Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC) - Loibl, S; Untch, M; Burchardi, N (J Clin Oncol, 2018)
et al.